Arcus Biosciences
RCUS
190 hedge funds and large institutions have $1.37B invested in Arcus Biosciences in 2025 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 65 increasing their positions, 61 reducing their positions, and 24 closing their positions.
2,013% more call options, than puts
Call options by funds: $46.2M | Put options by funds: $2.19M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
69% more capital invested
Capital invested by funds: $811M → $1.37B (+$557M)
25% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 24
3% more funds holding
Funds holding: 185 → 190 (+5)
7% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 61
0.36% more ownership
Funds ownership: 94.18% → 94.53% (+0.36%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$13.5M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$8.97M |
| 3 |
Fisher Asset Management
Camas,
Washington
|
+$6.66M |
| 4 |
DC
Decheng Capital
Menlo Park,
California
|
+$4.03M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$3.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$17M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$3.29M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.88M |
| 4 |
Jane Street
New York
|
-$2.67M |
| 5 |
State Street
Boston,
Massachusetts
|
-$2.45M |
RCUS Hedge Fund Activity: Q3 2025 in Review
190 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q3 2025, worth a combined $1.37B — up 69% from $811M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new RCUS positions and 24 closed out — a net gain of 6 holders — while 65 added to existing stakes and 61 trimmed.
The largest buyer was Siren LLC, adding an estimated $13.5M. The largest seller was Point72 Asset Management, cutting an estimated $17M.
- 190 institutional investors held Arcus Biosciences (RCUS) as of Q3 2025, up from 185 in Q2 2025.
- Funds reported $1.37B of Arcus Biosciences stock for Q3 2025, up 69% quarter-over-quarter.
- 30 funds opened new Arcus Biosciences positions in Q3 2025 and 24 closed out, a net change of +6 holders.
- The largest Arcus Biosciences buyer in Q3 2025 was Siren LLC, an estimated $13.5M added.
- The largest Arcus Biosciences seller in Q3 2025 was Point72 Asset Management, an estimated $17M sold.
Based on aggregated 13F filings for Q3 2025.